An Eli Lilly (LLY) spokesperson told Bloomberg that the company is in “active discussions” with the Trump administration on drug pricing after President Donald Trump announced the “first agreement with a major pharmaceutical company,” Pfizer (PFE), to bring American drug prices in line with the lowest paid by other developed nations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- White House announces deal with Pfizer for ‘most-favored-nation pricing’
- Trump says other drugmakers to join Pfizer with ‘most favored nation’ prices
- Big Tech’s AI Spending Could Surpass $2.8T by 2029, Says Citigroup
- Morning Wrap-Up: Monday’s Biggest Stock Market Stories!
- Eli Lilly’s (LLY) Weight-Loss Drugs May Benefit Alzheimer’s Patients